SOPHiA GENETICS Reports Q3 2026 Revenue Growth and Reaffirms Outlook
Revenue rose 25% year over year to $24.3 million. The company expects 2026 revenue at the upper end of its $94 million to $96 million guidance range.
SOPHiA GENETICS reported third-quarter 2026 revenue of $24.3 million, representing a 25% year-over-year increase. The company's adjusted EBITDA loss improved by 31% compared to the prior year period, while net loss was $20.3 million. Management highlighted record analysis volume on the SOPHiA DDM platform, 19% year-over-year volume growth, and strong performance in North America and Asia Pacific. The company also reported reaching 551 core genomics customers and closing three material BioPharma deals during the quarter.
Looking ahead, SOPHiA GENETICS expects full-year 2026 revenue to reach the upper end of its previously issued guidance range of $94 million to $96 million, noting potential headwinds from foreign exchange rate movements.